Inmunología Tumoral

Publicaciones

  • 01/09/2026

    Anticancer research

    HER2 and Other ErbB Receptors’ Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma

    María Alicia Cortés, Héctor Marcelo Marín, Rosalia Cordo-Ruso, Lucia Rott, Gustavo Emilio Giusiano, Luis Antonio Merino

  • 01/07/2026

    Cancer diagnosis & prognosis

    HER2 Expression and Nuclear Localization in Clear Cell Renal Cell Carcinoma: Implications for Prognosis and Therapeutic Targeting

    María Alicia Cortés, Héctor Marcelo Marín, Nadia Barbás, Rosalia Cordo-Ruso, Lucia Rott, Gustavo Emilio Giusiano, Luis Antonio Merino

  • 20/05/2026

    Molecular therapy. Oncology.

    Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma

    Bárbara Bueloni, Mariel Fusco, Esteban Fiore, Mariana Malvicini, María Jose Cantero, Lucía Lameroli, Mailín Casadei, Brian Martinez Ruiz, Florencia Mercogliano, Eva Santamaría, Catalina Atorrasagasti, Josepmaria Argemi, Ali Canbay, Juan Bayo, Guillermo Mazzolini

  • 27/04/2026

    Scientific report

    Human Tamm-Horsfall protein as a novel antitumor therapy for triple negative breast cancer and other solid tumors

    María Florencia Mercogliano, Sofia Bruni, Mara De Martino, Liliana Balanian, Miguel A Castellano, José Groisman, Felipe Inserra, Roxana Schillaci, Elena M V de Cavanagh

  • 27/10/2025

    International journal of molecular sciences

    4-Methylumbelliferone Modulates CAIX to Mitigate Hypoxia-Driven Dysregulation and Enhance PD-1 Immunotherapy in Lung Cancer

    Mariel Fusco, Carlos Rafael Picón, Marco Aurelio Diaz, Juan Bayo, Paula Constanza Arriola Benitez, Flavia Piccioni, Noelia Gómez, Mara Stinco, Javier Martínez Martinez, José Nicolás Minatta, Ricardo Amorín, Martina Villar, Valentina Sole, Ignacio Cassol, Mauricio De Marzi, Manglio Miguel Rizzo, María Florencia Mercogliano, Mariana Malvicini

  • 22/02/2025

    Translational oncology

    Mucin 4 expression is associated with metastasis in triple-negative breast cancer and can be tackled by soluble TNF blockade, improving immunotherapy outcome

    Florencia Mauro, Sofia Bruni, Agustina Dupont, Aldana Schey, Agustina Badalini, Gloria Inurrigarro, Silvina Figurelli, Sabrina Barchuk, Daniel Lopez Della Vecchia, Ernesto Gil Deza, Yanina Rivenson, Agustin Nava, Elmer Fernandez, Alejandro Urtreger, Rosalia Cordo Russo, María Florencia Mercogliano, Roxana Schillaci

  • 01/02/2024

    Nature reviews. Endocrinology

    Pituitary stem cells: past, present and future perspectives

    María Inés Pérez Millán, Leonard Y M Cheung, Florencia Mercogliano, Maria Andrea Camilletti, Gonzalo T Chirino Felker, Lucia N Moro, Santiago Miriuka, Michelle L Brinkmeier, Sally A Camper

  • 22/05/2023

    Frontiers in oncology

    Cancer immune exclusion: breaking the barricade for a successful immunotherapy

    Sofia Bruni, María Florencia Mercogliano, Florencia Luciana Mauro, Rosalia Inés Cordo Russo, Roxana Schillaci

  • 26/03/2023

    Cancers

    Emerging Targeted Therapies for HER2-Positive Breast Cancer

    María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci

  • Journal for Immunotherapy of Cancer

    01/03/2023

    Journal for immunotherapy of cancer

    Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

    Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci